Concert Pharmaceuticals Inc. (NASDAQ:CNCE) went up by 20.07% from its latest closing price compared to the recent 1-year high of $7.90. The company’s stock price has collected -2.82% of loss in the last five trading sessions.
Is It Worth Investing in Concert Pharmaceuticals Inc. (NASDAQ :CNCE) Right Now?
Plus, the 36-month beta value for CNCE is at 0.38. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Concert Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $17.40, which is $9.12 above the current price. CNCE currently public float of 43.92M and currently shorts hold a 5.00% ratio of that float. Today, the average trading volume of CNCE was 465.21K shares.
CNCE’s Market Performance
CNCE stocks went down by -2.82% for the week, with a monthly jump of 46.50% and a quarterly performance of 13.30%, while its annual performance rate touched 119.05%. The volatility ratio for the week stands at 8.46% while the volatility levels for the past 30 days are set at 9.67% for Concert Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 38.09% for CNCE stocks with a simple moving average of 59.33% for the last 200 days.
Analysts’ Opinion of CNCE
Many brokerage firms have already submitted their reports for CNCE stocks, with Berenberg repeating the rating for CNCE by listing it as a “Buy.” The predicted price for CNCE in the upcoming period, according to Berenberg is $25 based on the research report published on December 16th of the previous year 2020.
Jefferies, on the other hand, stated in their research note that they expect to see CNCE reach a price target of $23. The rating they have provided for CNCE stocks is “Buy” according to the report published on March 30th, 2020.
H.C. Wainwright gave a rating of “Buy” to CNCE, setting the target price at $25 in the report published on October 03rd of the previous year.
CNCE Trading at 57.43% from the 50-Day Moving Average
After a stumble in the market that brought CNCE to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 4.87% of gains for the given period.
Volatility was left at 9.67%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares surge +88.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.83% upper at present.
During the last 5 trading sessions, CNCE rose by +23.18%, which changed the moving average for the period of 200-days by +138.90% in comparison to the 20-day moving average, which settled at $6.19. In addition, Concert Pharmaceuticals Inc. saw 18.15% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CNCE starting from Tung Roger D, who sale 9,240 shares at the price of $7.24 back on Jan 06. After this action, Tung Roger D now owns 971,018 shares of Concert Pharmaceuticals Inc., valued at $66,898 using the latest closing price.
Stuart Nancy, the Chief Operating Officer of Concert Pharmaceuticals Inc., sale 2,893 shares at $7.25 during a trade that took place back on Jan 06, which means that Stuart Nancy is holding 281,844 shares at $20,974 based on the most recent closing price.
Stock Fundamentals for CNCE
Current profitability levels for the company are sitting at:
- -237.92 for the present operating margin
- +94.28 for the gross margin
The net margin for Concert Pharmaceuticals Inc. stands at -245.72. Equity return is now at value -114.10, with -79.90 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 9.32.